Table 3.
Pravastatin | p | Placebo | p | p | Healthy controls | ||||
---|---|---|---|---|---|---|---|---|---|
Pre-intervention | Post-intervention | Pre vs. post | Pre-intervention | Post-intervention | Pre vs. post | Pravastatin vs Placebo post | Control vs. pre-intervention T1DM | ||
Baseline flow velocity (m/s) | 0.23 ± 0.06 | 0.25 ± 0.07 | 0.29 | 0.22 ± 0.08 | 0.21 ± 0.06 | 0.31 | 0.08 | 0.22 ± 0.05 | 0.78 |
CPT flow velocity (m/s) | 0.33 ± 0.08 | 0.37 ± 0.14 | 0.22 | 0.31 ± 0.10 | 0.30 ± 0.10 | 0.61 | 0.11 | 0.41 ± 0.13 | 0.002* |
CPT flow/baseline flow (% increase) | 46 ± 24 | 51 ± 39 | 0.19 | 45 ± 46 | 49 ± 51 | 0.94 | 0.93 | 86 ± 45 | <0.001* |
Acceleration slope to the peak (1 /s) | 0.0074 ± 0.008 | 0.0147 ± 0.016 | 0.02* | 0.0069 ± 0.011 | 0.0047 ± 0.005 | 0.15 | 0.05* | 0.0084 ± 0.0054 | 0.06 |
Time to peak flow (s) | 58 ± 22 | 50 ± 21 | 0.18 | 55 ± 18 | 69 ± 25 | 0.16 | 0.02* | 39 ± 21 | 0.002* |
Baseline flow, maximal flow during CPT, the percent increase of flow during CPT, acceleration slope to peak flow velocity during CPT and the time to the peak mean diastolic velocity during CPT. The average acceleration (slope) to the peak = hyperemia to baseline value/time to attain the peak
p ≤ 0.05.